<DOC>
	<DOCNO>NCT01177566</DOCNO>
	<brief_summary>The purpose study assess bilateral comparison pimecrolimus cream 1 % ( Elidel® ) medical device cream ( EletoneTM ) treatment management atopic dermatitis . Study subject apply pimecrolimus twice daily four week target area locate one side body , apply medical device cream three time daily four week opposite side body target lesion symmetric .</brief_summary>
	<brief_title>Pimecrolimus Cream 1 % ( Elidel® ) Medicated Device Cream ( EletoneTM ) Treatment Maintenance Atopic Dermatitis .</brief_title>
	<detailed_description>Atopic dermatitis ( AD ) common chronic inflammatory skin disease affect large part population . Although atopic dermatitis respond well twice daily mid-strength corticosteroid , optimal expose patient long term use topical corticosteroid . Side effect long term steroid use include skin atrophy , stria , tachyphylaxis , adrenal suppression , bacterial infection , contact allergy name . Elidel® ( pimecrolimus ) cream 1 % Eletone™ cream alternative topical therapy FDA approve use patient atopic dermatitis . Each independent mechanism action show clinical trial deliver itch relief , reduce eczema flare maintain remission , thus provide adequate treatment option topical steroid prefer contraindicate . Thus far , study evaluate efficacy two product head-to-head . This investigator-blinded , bilateral comparison study 20 subject atopic dermatitis . It design assess compare efficacy Elidel® ( pimecrolimus ) cream 1 % Eletone™ cream patient atopic dermatitis . Subjects apply Elidel® ( pimecrolimus ) cream 1 % twice daily four week choose target eczematous area locate one side body apply Eletone™ three time daily symmetrical target eczematous area opposite side body . A randomized list create determine side subject applies medication . Patients clinically evaluate every two week investigator Physician Global Assessment ( PGA ) scale . Part clinical study consist use patient self-assessment questionnaire use non-identifying digital photography target lesion .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Males female ≥ 2 year old . Subjects must good general health confirm medical history physical examination . Females childbearing potential must negative urine pregnancy test baseline visit agree use adequate birth control study ( barrier , oral , injection , intrauterine ) . NOTE : Postmenopausal ( amenorrheic least one year ) surgically sterile ( tubal ligation and/or hysterectomy ) consider non childbearing potential . Clear diagnosis atopic dermatitis least one year . Subject must static Physician 's Global Assessment ( PGA ) least 2 ( mild severity ) select target lesion Disease must stable slowly worsen one week prior enter study . Subjects must able read , sign , date inform consent , abide study restriction duration . Females pregnant , attempt conceive , breastfeed . Subjects know hypersensitivity study drug . Subjects overt sign skin atrophy , telangiectasias and/or stria target area . Subjects current active skin malignancy infection . Subjects require use medication know alter course atopic dermatitis study treatment . Subjects received systemic antibiotic within 2 week . Subjects use systemic corticosteroid immunosuppressant within 28 day enter study . Subjects receive topical corticosteroid topical therapy ( tar , calcineurin inhibitor ) atopic dermatitis within 7 day enter study . Subjects use phototherapy ( UVB , PUVA ) within 28 day enter study . Subjects currently participate , previous 28 day , participate another study treatment atopic dermatitis . Subjects clinical condition may post health risk subject involve study detrimentally affect regular followup subject .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>Elidel</keyword>
	<keyword>pimecrolimus cream 1 %</keyword>
	<keyword>Eletone</keyword>
	<keyword>medical device cream</keyword>
	<keyword>topical calcineurin inhibitor</keyword>
</DOC>